Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-10-21
2000-05-30
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514428, 514448, 514457, 514651, A01N 4336, A01N 4316, A01N 4306, A01N 3302
Patent
active
060691751
ABSTRACT:
A method of treating atherosclerosis, independent of lipid lowering, in mammals, induding humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering certain estrogen agonist/antagonists.
REFERENCES:
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5254594 (1993-10-01), Niikura et al.
patent: 5407955 (1995-04-01), Bryant et al.
patent: 5426123 (1995-06-01), Fontana
patent: 5478847 (1995-12-01), Draper
patent: 5484795 (1996-01-01), Bryant et al.
patent: 5595722 (1997-01-01), Graomger et al.
patent: 5610168 (1997-03-01), Draper
Urabe, et al, Kyoto-furitsu Ika Daigaku Zasshi 104(12):1535-1544, 1995, "Atheroprotective affect of estrogen on human vascular cells".
Ross, Nature vol. 362, Apr. 29, 1993, p. 801-808, "The pathogenesis of atherosclerosis: a perspective for the 1990s".
Maija Kaartinen, et al., Accumulation of Activated Mast Cells in the Shoulder Region of Human Coronary Atheroma, the Predilection Site of Atheromatous Rupture, vol. 90, No. 4, Circulation, pp. 1669-1678, Oct. 1994.
Valentin Fuster, Mechanisms Leading to Myocardial Infarction: Insights from Studies of Vascular Biology, vol. 90, No. 4, Circulation, pp. 2126-2146, Oct. 1994.
Helen Wiseman, et al., Tamoxifen Inhibits Lipid peroxidation in Cardiac Microsomes, vol. 45, No. 9, Biochemical Pharmacology, pp. 1851-1855, 1993.
C. J. Schwartz, et al., The Pathogenesis of Atherosclerosis: An Overview, vol. 14, Clin. Cardiol., pp. I-1--I-16, Feb. 1991.
M. R. Frazier' Jessen, et al., Estrogen Modulation of JE/Monocyte Chemoattractant Protein-1 mRNA Expression in Murine Macrophages, Journal of Immunology, vol. 154, No. 4, pp. 1838-1844, 1995.
David J. Grainer, et al., Tamoxifen Elevates Transforming Growth Factor-.beta. and Suppresses Diet-induced Formation of Lipid Lesions in Mouse Aorta, vol. 1, No. 10, Nature Medicine, pp. 1067-1073, Oct. 1995.
Helen Wiseman, et al., Droloxifene (3-hydroxytamoxifen) has Membrane Antioxidant Ability: Potential Relevance to its Mechanism of Therapeutic Action in Breast Cancer, 66, Cancer Letters, pp. 61-68, 1992.
Benson Gregg C.
Collier Steven W.
Criares Theodore J.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Estrogen agonist/antagonists treatment of atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Estrogen agonist/antagonists treatment of atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Estrogen agonist/antagonists treatment of atherosclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1910757